- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
mCRC Treatment Access: IRA Cost Cap Impact and Final Insights
Medical experts discuss how the Inflation Reduction Act’s out-of-pocket prescription drug cost cap, effective in 2025, may impact access to oral chemotherapy options for metastatic colorectal cancer.
EP: 1.Navigating Beyond FOLFOX/FOLFIRI: Key Therapies in Advanced mCRC
EP: 2.Real-World Impact of SUNLIGHT Outcomes in mCRC
EP: 3.Fruquintinib in mCRC: Key Insights From FRESCO-2
EP: 4.Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib
EP: 5.Optimizing mCRC Therapy Sequencing: Key Considerations and Future Directions
EP: 6.Guiding Patients Through Third-Line mCRC Therapy Decisions
EP: 7.Navigating Toxicity: Comparing Third-Line mCRC Therapies
EP: 8.Evaluating Quality of Life and Adherence With mCRC Treatment Options
EP: 9.Integrating Support Services and Caregiver Roles in mCRC Care
EP: 10.mCRC Treatment Access: IRA Cost Cap Impact and Final Insights
Video content above is prompted by the following:
Concerning access to these oral chemotherapy options, how do you anticipate the Inflation Reduction Act’s out-of-pocket prescription drug cost cap will impact access to these metastatic colorectal cancer therapies starting in 2025?
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More
Ovarian Cancer Outcomes Linked to Preoperative Immunonutritional Status
February 18th 2025In patients with early-stage ovarian cancer, a high prognostic nutritional index improved survival, while a high systemic immune-inflammation index worsened it. In advanced stages, both affected overall survival but not progression-free survival.
Read More
